Nadav Kidron, Oramed CEO (website via YouTube)
Oramed’s insulin pill fails PhIII trial in diabetes, stock craters
Oramed Pharmaceuticals’ quest to develop an insulin pill for Type II diabetes just got stonewalled.
The biotech said its Phase III trial testing the oral …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
